| abstract |
The invention relates to N-acyl-N-heterocyclylalkylamino acids of the formula R1 is C1-C7alkyl that is unsubstituted or substituted by halogen or by hydroxy, or is C2-C7-alkenyl, C3-C7cycloalkyl, C3-C7cycloalkoxy, C1-C7alkoxy or C3-C7cycloalkyl-C1-C7alkoxy; R2 is 1H-tetrazol-5-yl, carboxy, C1-C7alkoxycarbonyl, SO3H, PO2H2, PO3H2 or halo-C1-C7alkanesulfonylamino; R3 is 1H-tetrazol-5-yl, hydroxymethyl, C1-C7alkoxymethyl, formyl, carboxy, C1-C7alkoxycarbonyl, C1-C7alkoxy-C1-C7alkoxycarbonyl, phenyl-C1-C4alkoxycarbonyl or carbamoyl, the amino group of which is unsubstituted or mono-substituted by C1-C7alkyl, C3-C7alkenyl or by phenyl-C1-C7alkyl or di-substituted by C1-C7alkyl, C3-C7alkenyl or by phenyl-C1-C7alkyl independently of one another, or is di-substituted by C2-C7alkylene or by C2-C4alkyleneoxy-C2-C4alkylene; Alk is methylene, ethylene or ethylidene; and their salts; preparation processes, pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and use. |